DEXCOM INC (DXCM) Insider Transactions

Reported filing row; may be amended. Do not sum filings blindly.

F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F3 Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2, F3

Reported filing row; may be amended. Do not sum filings blindly.

F1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F4 This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F5 Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

References: F1, F4, F3

Reported filing row; may be amended. Do not sum filings blindly.

F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F4 This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F5 Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

References: F1, F2, F3

Reported filing row; may be amended. Do not sum filings blindly.

F1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the Reporting Person is a trustee.

Exhibit 24 - Power of Attorney

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Included in this number are 8,691 unvested restricted stock units, 1,630 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,061 of which were granted on February 26, 2026 and shall vest through February 26, 2029.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Included in this number are 6,941 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 1,336 of which were granted on August 24, 2023 and shall vest through August 24, 2026.

Exhibit 24 - Power of Attorney

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the Reporting Person is a trustee.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.

Exhibit 24 - Power of Attorney

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

F2 Included in this number are 145,686 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

F3 Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

F2 Included in this number are 89,944 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

F2 Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

References: F1, F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

References: F1, F2